Enliven Therapeutics Stock Filter Stocks by Fundamentals
| ELVN Stock | 24.38 1.03 4.05% |
Enliven Therapeutics fundamentals help investors to digest information that contributes to Enliven Therapeutics' financial success or failures. It also enables traders to predict the movement of Enliven Stock. The fundamental analysis module provides a way to measure Enliven Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enliven Therapeutics stock.
Enliven | Shares Owned by Institutions |
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Enliven Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Enliven Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Enliven Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Enliven Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 899.44 M | ||||
| Shares Outstanding | 48.86 M | ||||
| Shares Owned By Insiders | 6.39 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 7.07 M | ||||
| Price To Book | 4.13 X | ||||
| EBITDA | (81.93 M) | ||||
| Net Income | (71.58 M) | ||||
| Total Debt | 335 K | ||||
| Book Value Per Share | 5,975 X | ||||
| Cash Flow From Operations | (61.27 M) | ||||
| Short Ratio | 29.73 X | ||||
| Earnings Per Share | (1.89) X | ||||
| Target Price | 37.17 | ||||
| Number Of Employees | 46 | ||||
| Market Capitalization | 1.24 B | ||||
| Total Asset | 271.87 M | ||||
| Retained Earnings | (154.45 M) | ||||
| Working Capital | 240.26 M | ||||
| Net Asset | 271.87 M |
About Enliven Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enliven Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enliven Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enliven Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.46 | HLN | Haleon plc | PairCorr |
| 0.42 | ANRO | Alto Neuroscience, | PairCorr |
| 0.4 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.35 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.35 | SHG | Shinhan Financial | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Enliven Therapeutics Piotroski F Score and Enliven Therapeutics Altman Z Score analysis. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.